Ohsu Knight Cancer Institute
Clinical trials sponsored by Ohsu Knight Cancer Institute, explained in plain language.
-
Experimental triple therapy aims to tame leukemia without intensive chemo
Disease control Recruiting nowThis phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Spinal chemotherapy may stop brain damage from cancer treatment
Disease control Recruiting nowThis phase 2 trial tests whether injecting chemotherapy drugs (cytarabine, methotrexate, and hydrocortisone) into the spinal fluid can prevent severe brain side effects in people receiving CAR T-cell therapy for blood cancers. About 20-70% of CAR T patients develop neurotoxicity,…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial is testing a radioactive drug called 177Lu-DOTATATE in 10 people with stage IV or recurrent breast cancer. The drug seeks out cancer cells that have a specific receptor (SSTR2) and delivers radiation to kill them. The goal is to see if it can shrink tumors and…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Less may be more: smaller surgery for melanoma tested in 1,000-Patient trial
Disease control Recruiting nowThis study tests whether removing a smaller border of healthy tissue around a melanoma (narrow excision) works as well as the standard wider excision. About 1,000 adults with early-stage melanoma will be randomly assigned to one of the two surgeries. The goal is to see if narrow …
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a website help prostate cancer survivors beat frailty?
Disease control Recruiting nowThis study tests an internet-based program called iLIVE that combines weight loss coaching and online exercise classes for men who have had hormone therapy for prostate cancer. The goal is to see if it can reduce obesity and frailty, which are common side effects of treatment. Re…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy targets tough lymphoma in early trial
Disease control Recruiting nowThis study tests whether adding mosunetuzumab, an antibody that helps the immune system attack cancer, to standard chemotherapy can safely treat aggressive B-cell lymphomas. About 30 adults with untreated high-grade or diffuse large B-cell lymphoma will receive the combination. R…
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising new combo tackles tough leukemia
Disease control Recruiting nowThis study tests a new mix of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment combines a targeted drug (venetoclax) with two chemotherapy drugs, then switches to another chemo drug plus venetoclax. The goal is to see if this ap…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to tackle tough lymphoma in vulnerable patients
Disease control Recruiting nowThis study tests a combination of three drugs—glofitamab, ibrutinib, and obinutuzumab—in people with mantle cell lymphoma who are either 65 or older, or between 18 and 64 with high-risk features. The goal is to see if the combo is safe and can shrink or eliminate tumors. Particip…
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising new combo aims to wipe out leukemia cells more effectively
Disease control Recruiting nowThis phase 2 trial is testing whether adding the targeted drug venetoclax to a standard chemotherapy regimen (FLAG IDA) works better than the usual treatment for adults newly diagnosed with acute myeloid leukemia (AML). About 102 participants will receive either the new combinati…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New stem cell filter could reduce transplant rejection
Disease control AVAILABLEThis study offers a special stem cell transplant to people with cancer or other disorders who lack a perfectly matched donor. Doctors use a device to purify stem cells from a partially matched donor, removing immune cells that can cause rejection or attack the patient's body. The…
Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and effective for people with advanced or metastatic solid tumors. The study will enroll 38 adults whose cancer has spread or not responded to prior treatment. Researchers …
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo aims to outsmart High-Risk leukemia
Disease control Recruiting nowThis phase 1 trial is testing whether adding the targeted drug pemigatinib after standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML). Pemigatinib blocks a protein called FGFR that may fuel leukemia growth. The study will enroll 32 adults with i…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New triple therapy shows promise for blood cancer patients
Disease control Recruiting nowThis early-phase study tests whether combining three drugs (tafasitamab, acalabrutinib, and obinutuzumab) is safe and effective for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to control the cancer by targeting differe…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Double contrast MRI could sharpen brain diagnosis
Diagnosis Recruiting nowThis study tests whether using two contrast agents (gadolinium and ferumoxytol) in one MRI session can improve the detection and diagnosis of brain and central nervous system abnormalities. About 150 participants with neurological symptoms or known brain lesions will undergo imag…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Heart drug may stop common complication after esophageal cancer surgery
Prevention Recruiting nowThis study tests whether giving the drug amiodarone after minimally invasive esophageal cancer surgery can prevent a common complication called atrial fibrillation (an irregular, often rapid heart rhythm). About 90 adults having this surgery will be randomly assigned to receive e…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:36 UTC
-
Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
Symptom relief Recruiting nowThis trial tests a web-based program called COMPASS that provides personalized exercise and nutrition advice, along with text messages, activity trackers, and coaching, for people with stage I-III pancreatic cancer receiving chemotherapy before surgery. The goal is to see if the …
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Exercise with friends may ease cancer loneliness in older men
Symptom relief Recruiting nowThis study tests whether exercising with others, including some social time, can reduce feelings of loneliness in older men (65+) who have had prostate cancer. 150 participants will be assigned to one of three groups: socially enhanced group exercise, regular group exercise, or e…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Art as medicine: new study tests if painting eases cancer symptoms in kids
Symptom relief Recruiting nowThis study looks at whether doing creative arts like drawing, painting, or making sculptures can help children with cancer feel better and improve their quality of life. About 72 children aged 8 to 13 who were diagnosed with cancer in the past year will take part. Some will do ar…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Can a common drug help cancer patients regain appetite?
Symptom relief Recruiting nowThis study tests whether olanzapine, a drug already used for other conditions, can help cancer patients who are losing weight and appetite. About 66 adults with advanced lung, stomach, or bowel cancers will receive either olanzapine or a placebo. The goal is to see if olanzapine …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Can a conversation aid empower lung cancer patients?
Knowledge-focused Recruiting nowThis study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New drug OMO-103 tested in early pancreatic cancer trial
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after trea…
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Pancreatic cancer drugs put to the test in early trial
Knowledge-focused Recruiting nowThis early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Free genetic testing offered to 27,500 people to find hidden cancer risks
Knowledge-focused Recruiting nowThis study offers free genetic testing to the general public to identify people with inherited cancer syndromes like hereditary breast and ovarian cancer or Lynch syndrome. Researchers aim to see if broad testing is more effective than only testing those with a family history. Up…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Fiber supplements may alter gut bacteria linked to colon cancer risk
Knowledge-focused Recruiting nowThis trial is testing whether taking daily fiber supplements can change the types and amounts of bacteria living in the colon. The study involves 120 adults with benign anal or colorectal conditions who are not currently on fiber supplements. Researchers will compare gut bacteria…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Do men and women react differently to immunotherapy? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Timing matters: study seeks best moment for PSMA scans after hormone therapy
Knowledge-focused Recruiting nowThis study looks at how hormonal therapy changes PSMA levels in men with prostate cancer, both in early and advanced stages. Researchers will use PSMA PET scans at different times after starting therapy to see when the scan is most accurate for staging the cancer. The goal is to …
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Blood test may predict which rectal cancer patients can skip surgery
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if chan…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
CAR-T therapy may erase vaccine immunity, new study warns
Knowledge-focused Recruiting nowThis study looks at whether CAR-T cell therapy reduces the body's ability to fight off diseases like measles and mumps that were previously prevented by vaccines. Researchers will measure antibody levels in 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after …
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:22 UTC